Core Viewpoint - The report highlights that Innovent Biologics (01801) achieved a 38% year-on-year revenue increase to 13 billion RMB, with a net profit of 834 million RMB, marking a return to profitability [1] Financial Performance - Revenue for the last year reached 13 billion RMB, reflecting a 38% increase compared to the previous year [1] - The company reported a net profit of 834 million RMB, indicating a turnaround from previous losses [1] Management Guidance - Management reiterated the sales target of 20 billion RMB for 2027 [1] - Despite recent price adjustments and increased competition, sales of Mazdutide continue to show strong momentum [1] Analyst Adjustments - Citigroup raised the revenue forecasts for the company by 24% and 23% for this year and next year, respectively [1] - Earnings per share estimates were increased by 33% and 5% for the same periods [1] - The target price for the stock was raised from 110 HKD to 115 HKD, maintaining a "Buy" rating [1]
花旗：升信达生物目标价至115港元 评级“买入”